Latest Breaking News On - Reduced ejection - Page 2 : comparemela.com

Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch® Ventricular Restor

Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection FractionSANTA CLARA, Calif. (BUSINESS WIRE) #accucinch Ancora Heart, Inc., a company developing a novel device-based therapy to address heart.

Cytokinetics Announces Topline Results From METEORIC-HF

No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction Results Will Be Presented in Late Breaking Clinical Trial Session at the American. | February 15, 2022

Stem Cell Therapy for Heart Failure Reduced Major Cardiac Events and Death

But DREAM-HF trial saw no reduction in hospitalizations for heart failure events among adults with heart failure who received a stem cell treatment

Appendix 4C Quarterly Activity Report

Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.